Remove 2015 Remove FDA Remove Immunization
article thumbnail

Pneumococcal Vaccine Rates Low Despite Updated Recommendations

Drug Topics

In 2022, the Advisory Committee on Immunization Practices (ACIP) published updated pneumococcal vaccine recommendations. Increasing pneumococcal vaccine uptake is especially important in light of the recent COVID-19 pandemic that disrupted routine immunization services and highlighted the vulnerability of adults to respiratory infections.”

article thumbnail

Op-Ed: States Are Leading the Way on PBM Reform. Here’s How.

Pharmacy Times

3 In 2015, when PBMs were still largely flying under the radar for most federal lawmakers, Arkansas passed a first-in-the-nation law that required these groups to reimburse independent pharmacies no less than what pharmacies paid to acquire the prescription medications they filled.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Carefully Monitor Direct Oral Anticoagulant Medications

Pharmacy Times

Although some of these medications have additional FDA-approved uses (ie, rivaroxaban to reduce the risk of thrombotic vascular events in patients with peripheral artery disease), all 4 DOACs are approved for the treatment and prevention of venous thromboembolism and stroke prevention in nonvalvular atrial fibrillation (AFib). link] Eliquis.

article thumbnail

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Pharmacy Times

The FDA approval process for biologics is lengthier compared with biosimilars. Darkow explained that this is because the FDA mandated that biosimilars must have the same core name as the reference product but must remain identifiable.

article thumbnail

Correct Patient Misconceptions Around Biosimilars

Pharmacy Times

Image credit: Shutter2U | stock.adobe.com Biosimilars are biologic products highly similar to an FDA-approved reference product, with no clinically meaningful differences in safety, purity, or potency. Misconceptions can lead to unnecessary hesitation, increased health care spending, and reduced access to important biologic treatments.

article thumbnail

Results Find SGLT2 Inhibitors Associated With Erythrocytosis

Drug Topics

Patients were 18 years and older with type 2 diabetes and were included from January 1, 2015, through June 30, 2024. SGLT2i include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, which are approved to treat type 2 diabetes by improving blood sugar. The drugs can prevent reabsorption of filtered glucose from the tubular lumen.

article thumbnail

ADA: Vertex closer to weaning type 1 diabetics off insulin

pharmaphorum

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)